In this article
UNIGE Study: Resveratrol for Lung Cancer Prevention
Some research shows eating grapes may prevent cancer. Lung malignancy is the deadliest type of tumor on the planet, and 80% of deaths are associated with smoking. Notwithstanding tobacco control, compelling chemoprevention techniques are in this way required. A group of researchers from the University of Geneva (UNIGE), Switzerland, examined an outstanding regular item, resveratrol, which is found in grapes and in red wine.
While its chemopreventive properties against growths influencing the stomach related tract have been archived by past examinations, resveratrol has so far demonstrated no impact on lung malignancies. On account of nasal organization, the UNIGE group got exceptionally encouraging outcomes in an investigation directed in mice and depicted in the diary Scientific Reports.
Overcoming Bioavailability with Nasal Administration
In any case, resveratrol does not appear to be reasonable for forestalling lung malignancy: when ingested, it is used and killed within minutes, and in this manner, it does not have sufficient energy to reach out to the lungs. “This is the reason our test was to discover a manner in which resveratrol could be solubilized in extensive amounts, despite the fact that it is inadequately dissolvable in water, with a specific end goal to permit nasal organization. This plan, relevant to people, enables the compound to achieve the lungs,” clarifies Aymeric Monteillier, a researcher in the School of Pharmaceutical Sciences of the UNIGE Faculty of Science, and the principal creator of the examination.
The resveratrol fixation acquired in the lungs after the nasal organization of the definition was 22 times higher than when taken orally. The chemoprevention instrument is most likely identified with apoptosis, a procedure by which cells program their own demise and from which tumor cells escape. The UNIGE investigation group will now center around finding a biomarker that could add to the determination of individuals qualified for preventive treatment with resveratrol.
Commercial Viability and Future Preventive Treatments
Resveratrol is a well-known molecule that is found in nourishment supplements, implying that no further toxicological examination would be required before commercialization as a preventive treatment. “This revelation is shockingly minimal financial enthusiasm for pharmaceutical gatherings. The particle is undoubtedly basic and non-patentable, and tumor avoidance thinks about requiring a follow-up over numerous years,” laments Muriel Cuendet, without barring the advancement of preventive treatment in people.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.